Orthofix Medical Inc (OFIX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Orthofix Medical Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 11 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 11.80 $ — 39% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 21.3% passed
- More than 10% revenue growth is expected for the coming year 5.2% failed
- Share count grows by less than 3% a year 25.7% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 2.7% failed
- Gross margin at 40% or higher and without meaningful erosion 67.1% passed
- Goodwill from acquisitions does not grow faster than revenue 22.9% failed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 383 m passed
- Return on capital at 15% or higher, or up versus two years ago -10.1% failed
- Insiders hold at least 10% or are net buyers 2.2% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 31.4% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 5
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.27 | 0.27 – 0.27 | 843 | -44.6% | 1 |
| 12/31/2027 | 0.84 | 0.29 – 1.39 | 886 | 211.1% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.46 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.75 | – | 216 | 7.60 | -13.50 | 24 | 15 |
| 2025: Q1 | -1.35 | – | 194 | 2.70 | -27.40 | -18 | -25 |
| 2025: Q2 | -0.36 | – | 203 | 2.30 | -6.90 | 12 | 5 |
| 2025: Q3 | -0.57 | – | 206 | 4.60 | -11.10 | 12 | 3 |
| 2025: Q4 | -0.06 | – | 220 | 2.00 | -1.00 | 29 | 18 |
| 2026: Q1 | -0.52 | – | 197 | 1.60 | -10.60 | -18 | -28 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 410 | 21 | 3 | 0.17 | 45 | 263 | 372 |
| 2017 | 434 | 41 | 6 | 0.34 | 53 | 297 | 405 |
| 2018 | 453 | 30 | 14 | 0.73 | 50 | 335 | 467 |
| 2019 | 460 | -19 | -28 | -1.51 | 32 | 328 | 496 |
| 2020 | 407 | -6 | 3 | 0.13 | 74 | 357 | 526 |
| 2021 | 464 | -8 | -38 | -1.95 | 18 | 337 | 477 |
| 2022 | 461 | -13 | -20 | -0.98 | -12 | 337 | 459 |
| 2023 | 747 | -139 | -151 | -4.12 | -46 | 599 | 925 |
| 2024 | 799 | -85 | -126 | -3.30 | 26 | 503 | 893 |
| 2025 | 822 | -68 | -92 | -2.31 | 33 | 450 | 851 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Orthofix Medical Inc. , together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally.
| Employees | 1,605 |
|---|---|
| Headquarters | Lewisville, TX |
| Address | 3451 Plano Parkway, 75056 Lewisville, United States |
| Phone | 214 937 2000 |
| Website | orthofix.com |
| IPO Date | 24. Apr 1992 |
| ISIN | US68752M1080 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Massimo Calafiore | President, CEO & Director | 1972 |
| Julie B. Andrews | Chief Financial Officer | 1971 |
| Aviva McPherron | President of Global Operations & Quality | 1977 |
| J. Andres Cedron | Chief Legal Officer & Corporate Secretary | 1981 |
| Patrick Fisher | President of Global Biologics & Limb Reconstruction | 1974 |
| Geoffrey C. Gillespie | Chief Accounting Officer | – |
| Julie D. Dewey | Chief Investor Relations & Communications Officer | 1961 |
| Jill Mason | Chief Compliance & Risk Officer | – |
| Stephanie Walsh | Chief Human Resources Officer | – |
| Beau Standish P.Eng., Ph.D. | Chief Enabling Technologies Officer | 1980 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.